ABSTRACT
Social media significantly affects how patients understand their health and choose their healthcare providers, yet Australian dermatologists have a limited online presence compared to their global peers.
ABSTRACT
Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.
Subject(s)
Pre-Eclampsia , Biomarkers , Female , Humans , Longitudinal Studies , Placenta Growth Factor , Pre-Eclampsia/diagnosis , Pregnancy , Prospective Studies , Receptor Protein-Tyrosine Kinases , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor Receptor-1ABSTRACT
Objective:To compare the effect of comorbidities on the phenotype and outcomes of preeclampsia.Methods: A matched retrospective cohort study of women delivering at a tertiary maternity center following a diagnosis of preeclampsia. We collected data on signs and symptoms, biochemical markers, and maternal and perinatal outcomes.Results:We studied 474 women; 158 women with and 316 without comorbidities. Compared to women without comorbidities, women with comorbidities delivered earlier. They suffered fewer maternal but more neonatal complications.Conclusion: Women with comorbidities receive earlier intervention than women without comorbidities, which may lead to fewer maternal complications but worse neonatal outcomes.
Subject(s)
Angiogenic Proteins/blood , Biomarkers/blood , Hypertension/epidemiology , Infant, Newborn, Diseases/epidemiology , Pre-Eclampsia/diagnosis , Pregnancy Complications/diagnosis , Adult , Angiogenic Proteins/analysis , Biomarkers/analysis , Comorbidity , Female , Humans , Infant, Newborn , Infant, Newborn, Diseases/blood , Phenotype , Pre-Eclampsia/blood , Pre-Eclampsia/epidemiology , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/epidemiology , Pregnancy Outcome/epidemiology , Retrospective StudiesABSTRACT
Placental growth factor (PlGF), total soluble fms-like tyrosine-kinase 1 (sFlt-1) and its placental-specific variant, sFlt-1 e15a, show promise as biomarkers for the prediction and diagnosis of preeclampsia. This study describes the degradation of PlGF, sFlt-1 and sFlt-1 e15a within maternal serum and plasma to assist clinical implementation. Whole blood was refrigerated at 4⯰C for up to 48â¯h prior to centrifugation for isolation of plasma and serum. PlGF and sFlt-1 were quantified using the B.R.A.H.M.S Kryptor Compact PLUS; sFlt-1 e15a via a custom ELISA. All three analytes are stable for at least 48â¯h at 4⯰C. Serum and plasma performed comparably.
